EMA Authorised: Fasturtec (rasburicase) — Sanofi Winthrop Industrie

View source ↗

Summary

The EMA authorised Fasturtec (rasburicase) by Sanofi Winthrop Industrie for hyperuricemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperuricemia

Drugs mentioned

• Fasturtec (rasburicase)

Snippet

Status: Authorised. Therapeutic area: Hyperuricemia. MAH: Sanofi Winthrop Industrie. Decision date: 13/05/2024